

LC-MS Solutions for Biopharmaceutical Characterisation

Craig Jakes^{1,2}, Tomos Morgan¹, Sara Carillo¹, Silvia Millán-Martín¹, Florian Füssl¹, Felipe Guapo¹,
Lisa Strasser¹, Josh Smith¹ and Jonathan Bones^{1,2}

¹National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merrion, Co. Dublin, A94 X099, Ireland

²School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland

NIBRT Overview



- World-class facility dedicated to address the training and research needs of the global biopharmaceutical industry based in Dublin, Ireland
- Competency based training experience in an environment that replicates modern industrial bioprocessing facilities
- Research with impact – developing solutions to address real challenges faced within the biopharmaceutical industry
- Proud to collaborate with Thermo Fisher Scientific to demonstrate the power of their world leading instrumentation, software and consumables for biopharmaceutical characterisation




New NIBRT Initiatives in 2023



- Facility expansion opening in Q3.
- Dedicated suites for cell and gene therapy manufacture training activities.
- New research labs for expanded research teams.


Expansion will also contain a new early stage development facility designed to serve the research community funded by Science Foundation Ireland.



Protein based biopharma workflows

Intact Protein Analysis


- Intact mAbs
- ADC profiling
- Charge variant and aggregate analysis
- mAb subunit analysis




Intact mAb or ADC, e.g.
in formulation buffer



SEC, SCX or
RP separation



Sensitive Full MS detection of intact
proteins in native or denatured state




Spectral deconvolution using
sliding windows feature for most
sensitive deconvolution or species
of high and low abundance

Peptide Analysis

- Peptide mapping
- HCP analysis
- Multi-Attribute Method (HR-MAM)




Intact mAb



Digestion with
SMART™ digest-kit



High performance
peptide separation



HRAM detection with fragmentation
supporting identification




Software supporting sequence confirmation,
PTM identification and quantitation, CQA
monitoring, and HCP identification

HDX Analysis


- Any Orbitrap-based system can be coupled to the H/D-X PAL/LC front end





Intact mAb



Deuterium-labelling over time course with
in-line digestion followed by fast separation




HRAM mass detection providing isotope
pattern for monitoring of deuterium uptake.



Software solution for peptide identification, PTM analysis,
top-down and bottom-up HDX data analysis.

Large Molecule Bioanalysis

- Analysis on the peptide level
- Analysis on the protein level




Digestion with
SMART™
digest-kit


Enrichment by affinity
capture with MSIA
microcolumns




High performance
peptide and protein
separation




- Fragmentation supporting peptide ID
- Full MS for intact protein analysis



MAM workflows




Protein based therapeutics workflows




Intact Protein Workflows

Why Intact Mass Analysis?


1. Quick and easy, no or very limited requirement for sample preparation




2. No sample preparation induced modifications




3. Assembly of differently modified residues into intact proteoforms known



Intact Mass Analysis on Orbitrap Exploris 240 MS




Intact mass analysis of Infliximab performed using RP-MS
on a Thermo Scientific™ MAbPac™ RP column and
acetonitrile/water containing 0.1% FA gradient




Beautiful spectra collected for intact denatured infliximab with excellent resolution of the glycoforms present for each individual charge state, shown on next slide

Evaluation of Mass Stability

Analysis was performed on a daily basis to evaluate the mass stability of the instrument without EASY-IC source calibration, data processing standardised in Biopharma Finder software




ppm mass accuracy determined and plotted to assess instrument stability on a day by day basis for up to 18 days with no calibration




Intact Mass Analysis of Stressed Ipilimumab

Charge envelope of intact control and stressed Ipilimumab (500 ppm H₂O₂) and zoom of +52 charge state representing a baseline resolved glycoform pattern




Analysis of Subunits following IdeS Digestion



Ipilimumab digested with IdeS protease followed by reduction, resulting subunits separated on MAbPac RP column on Vanquish Duo UHPLC coupled to Orbitrap Exploris 240 MS




A More Detailed





A More Detailed Look at the LC




Zoomed mass spectra acquired with $R_s = 120,000$ (at m/z 200) showing baseline-resolved isotope patterns of the +25 charge state of the light chain



A More Detailed Look




Zoomed mass spectra acquired with
Rs = 120,000 (at m/z 200) showing
baseline-resolved isotope patterns of
the +26 charge state of the Fd




Forced Oxidation of Ipilimumab

We subjected Ipilimumab to forced oxidation using peroxide treatment and repeated subunit analysis following IdeS digestion and reduction



TIC of separated GOF glycoform of ipilimumab scFc for control and stressed samples (50 and 500 ppm H_2O_2)




Zoomed mass spectra acquired with $\text{Rs} = 120,000$ (at $m/z 200$) showing near baseline-resolved isotope patterns of the +28 charge state of the scFc GOF subunit

Deconvolution of the entire charge envelope including all scFc subunit glycoforms using Sliding Window Xtract algorithm



Forced Oxidation of Ipilimumab

Deconvolution of the subunit spectra revealed modifications on the heavy chain only, no oxidation on the light chain. An additional oxidation was noted on the Fd region of the heavy chain as well as those previously noted on the scFc region




Pseudo extracted ion chromatograms following sliding window deconvolution for all detected forms of the scFc, LC and Fd subunits



Subunit Analysis also applies to IgG1 Fc



Zoomed mass spectra acquired with
Rs = 120,000 (at m/z 200) showing
near baseline-resolved isotope
patterns of the +28 charge state of the
scFc glycoforms




Subunit Analysis a





24+ Golimumab


Zoomed mass spectra acquired with
Rs = 120,000 (at m/z 200) showing
baseline-resolved isotope patterns of the
+24 charge state of the light chain






Subunit Analysis also applies to Fab




Zoomed mass spectra acquired with
Rs = 120,000 (at m/z 200) showing
baseline-resolved isotope patterns
of the +26 charge state of the Fd



Forced Oxidation of Golimumab scFc Sub Unit



Peptide Mapping on Orbitrap Exploris 240 MS





Base Peak Chromatogram of denosumab (Prolia™) indicating the peptide origin to light or heavy chains indicated by red (light chain) and green (heavy chain)

Peptide Mapping on Orbitrap Exploris 240 MS

Data searched using Biopharma Finder software, 100% sequence coverage obtained for denosumab light and heavy chains. Coloured bars represent identified peptides with colours indicating peptide intensities based on full MS spectra


Sequence Coverage Map



Data generated by Tom Buchanan, European Applications Development Scientist at Thermo Fisher Scientific


Peptide Mapping on Orbitrap Exploris 240 MS

Experiment was repeated using without reduction to keep disulphide bonds intact, coloured bars represent identified peptides intensities based on full MS spectra




Data generated by Tom Buchanan, European Applications Development Scientist at Thermo Fisher Scientific

Low Level Peptide Modifications



Detection of deamidation at ^{366}N in denosumab heavy chain, extracted ion chromatograms, MS and MS/MS spectra indicated induced mass shift in b-ions


Disulphide Bond Mapping on Orbitrap Exploris 240 MS




S-S Bond Type	Peptide Sequence	Position	Δ ppm	RT
Intra Chain	LC1 ATLS <i>CR</i> / LEPEDFAVFY <i>CQQYGSSPR</i>	1:C23/1:C89	-1.2	25.95
	LC2 SGTASVV <i>CLLNINFYPR</i> / HKVY <i>A</i> CEVTHQGLSSPVTK	1:C135/1:C195	-2.1	24.15
	HC1 LS <i>CAASGFTFSSYAMS</i> WVR / AEDTAVYY <i>CAK</i>	2:C22/2:C96	-2.7	28.95
	HC2 STSESTAALG <i>CLVK</i> / DYFPEPVTV <i>SWNSGALTSGVHTFP</i> AVLQSSGLYS <i>LSSVTV</i> PSSNFGTQT <i>YT</i> C <i>NVDHKPSNTK</i>	2:C149/2:C205	-0.9	32.54
	HC3 TPEVT <i>CVVV</i> DVS <i>HEDPEVQFNWY</i> V <i>DGVEVHN</i> AK / <i>CK</i>	2:C262/2:C322	-0.6	26.76
	HC4 NQVSLT <i>CLVK</i> / WQQGNV <i>FSCSVMHEALHNHYTQK</i>	2:C368/2:C426	0.4	22.87
Inter Chain	LC-HC G <i>E</i> C / GPSV <i>FPLAPCSR</i>	1:C215/2:C136	-2.5	21.86
	Hinge KCCVE <i>CPPCPAPPVAGPSVFLFPPKPK</i> / K <i>CCVE</i> <i>CPPCPAPPVAGPSVFLFPPKPK</i>	2:C224, C225, C228, C231/2:C224, C225, C228, C231	-0.02	28.05

Back to Ipilimumab: Oxidation on the Peptide Level


TIC zoom of the control (upper) and stressed (lower) ipilimumab after digestion, highlighting 'DTLMISR' heavy chain peptide



Zoom spectra of DTLMISR displaying isotope patterns and relative abundances of the doubly-charged peptides with <1 ppm mass accuracy, selected for HCD fragmentation



MS/MS fragment ion spectra for mass range m/z 300 - 900. Identification supported by +15.9949 Da shifts for y_4 and y_5 fragment ions and diagnostic loss of methane sulfenic acid (CH_3SOH) in the oxidized peptide




Data generated by Tom Buchanan, European Applications Development Scientist at Thermo Fisher Scientific


Sub unit analysis of mAbs is a pretty standard workflow

Sub unit analysis of mAbs using reduction, IdeS protease digestion or both is a common but laborious workflow


Use of online electrochemical reduction such as the Antec® Scientific ROXY™ Exceed potentiostat offers the potential to minimise sample handling and sample preparation steps



Inline electrochemical reduction with ROXY™ Exceed






Coupling Roxy™ Exceed potentiostat inline to LC-MS




- Experimental design of inline electrochemical reduction using a dual pump and trap column setup
- Allows use of solvents optimised for best reduction conditions followed by best conditions for analysis



Optimisation of inline electrochemical reduction



Optimisation of inline electrochemical reduction



Increasing temperature and organic content overcomes kinetic barrier and allows inter- and intra-chain reduction




Light Chain


Heavy Chain



Combination with IdeS digestion




Inline reduction of IdeS
digested mAb using ROXY™
Exceed potentiostat inline
with LC-MS




Native Separations Coupled to Native MS

Why Native MS?


1. Preservation of higher order protein structure allows for structural analysis, e.g. structural changes upon pH change, ligand binding, complex formation, etc.




2. Spectra in the higher m/z range with increased spatial spectral resolution



3. Preservation of non-covalent interaction allows for the analysis of fragile molecules such as cysteine-conjugated antibody-drug conjugates






Native SEC-MS on Orbitrap Exploris 240 MS



Deconvoluted spectrum of trastuzumab from SEC-MS dilution series data, excellent mass accuracy across the glycoform distribution

Native SEC-MS on Orbitrap Exploris 240 MS

Dilution series for trastuzumab using native SEC-MS, excellent instrument sensitivity and linearity. Beautiful native, deconvolutable spectra acquired even down to 50 ng on column!




Particle Size and Chromatographic Performance

- Reducing the particle size of chromatographic stationary phases is well known to increase the efficiency of the separation due to reduced plate height.
- Advances in stationary phase formats have enabled the achievement of high chromatographic efficiency without the associated increase in pressure that arises when using particles with small diameters.
- However, stationary phase particles are often polydisperse, resulting in a range of particles, some smaller and some larger than the stated particle size, which effects column performance according to van Deemter.
- Monodisperse particle size distributions represent a more idealised stationary phase format, reducing diffusive effects and facilitating more reproducible mass transfer, together yielding increased chromatographic performance.


Introducing a Novel Monodisperse Particle Technology

- Thermo Scientific have developed new ion exchange phases based on a novel monodisperse particle technology – ProPac 3R Range.
- Columns are packed with a 3 µm monodisperse non-porous polymeric phase, coated with a hydrophilic polymeric layer comprising anion or cation exchange functionalities.
- Column features include:
 - Increased capacity,
 - Ability to use shorter formats to increase speed,
 - Increased chromatographic performance,
 - Excellently controlled chemistry of manufacture yielding tight batch-to-batch reproducibility.

Chromatographic Reproducibility on ProPac 3R




Lot-to-Lot Reproducibility of the Packing Material




Three manufacturing lots of ProPac 3R
3 μm used to evaluate lot-to-lot
reproducibility of the packing material
using adalimumab with 40-100% B pH
gradient elution.

pH Gradient Reproducibility




Excellent reproducibility of pH gradient formation and column re-equilibration with linearity present in the pH gradient yielding the observed selectivity.

High Resolution: pH Gradient MS Coupling





- Sample amount 50 µg
- Excellent MS sensitivity
- Peaks can be clearly distinguished in the sub 1% relative abundance region
- Clear mass spectra obtained for all major peaks
- Even peaks with a relative abundance of 0.4% (**A5**) show spectral quality sufficient for deconvolution.




High Resolution: pH Gradient MS Coupling

Deconvolution of the data using the Sliding Window algorithm in BioPharma Finder facilitates assessment and annotation of peaks, from high to low abundance.




High abundant species, *e.g.*, A1 easily identified as des-C-term K form. Selectivity on SCX-MD 3 μm is so good that we now can identify lower abundant proteoforms of the molecule, tentative identification based on mass, confirmation by peptide mapping


Comparability Assessment - Adalimumab



Baseline Zoom – Impressive Selectivity of SCX-MD 3μm



Comparability Assessment of Adalimumab Biosimilars




iMAM Data Processing

Carillo et al., Eur J Pharm Biopharm, 2022, 177, 241-248.

Characterization



LC-MS



Thermo Scientific™ Vanquish™ UHPLC
Thermo Scientific™ Orbitrap Exploris™ 240

Deconvolution
and
search




Thermo Scientific™
BioPharma Finder™ v. 4.1

Processing method for
target components
monitoring




Thermo Scientific™
Chromeleon™ CDS


Monitoring




LC-MS



Compliant report generation
and new entities search




Comparability Assessment of Adalimumab Biosimilars



iMAM processing of the resulting MS data enables the determination and quantitation of a large number of product quality attributes present on the intact level


Simplified output depicting only the C-term lysine variants used to compare the different adalimumab biosimilars

iMAM Processing of Adalimumab CEX-MS Data



Improved selectivity of ProPac 3R SCX improves iMAM processing allowing for more components to be identified and added to the processing method for targeted quantitation and reporting.


An Additional Basic Peak Present in Yuflyma



Native MS spectrum of peak present at 15.5 mins, features indicated with the yellow stars appearing at a lower m/z value were selected and deconvoluted

Yuflyma was found to contain an extra peak in the basic region of the chromatogram, at 15.5 minutes, eluting later than any other peak present in the innovator or other adalimumab biosimilars.

An Additional Basic Peak Present in Yuflyma




Deconvoluted mass spectra of Yuflyma and the innovator product were compared.

An additional peak at 147,294.25 Da was observed in Yuflyma.

Working the numbers, this lower mass species potentially corresponds to a truncation on the heavy chain N-terminus.

Confirmation of HC N-term Cleavage by Pep Mapping



Coupling ProA affinity chromatography to high res MS



analytical
chemistry

Anal. Chem. 2015, 87, 2023-8

Editors' Highlight
pubs.acs.org/ac

Inline Protein A Mass Spectrometry for Characterization of Monoclonal Antibodies


Kenneth M. Prentice, Alison Wallace, and Catherine M. Eakin*,†

Department of Analytical Sciences, Amgen Inc, 1201 Amgen Court West, Seattle, Washington 98119, United States

Previous report from Amgen on ProA coupling to MS but used solvent make up flow for denatured intact mass analysis

Protein A affinity chromatography is a key step in the purification of mAbs and Fc fusion proteins


We also routinely use the Thermo Scientific™ MAbPac™ Protein A Antibody Analysis and Purification HPLC Column for rapid titre determination by LC-UV




We wanted to explore if we could couple ProA to high resolution Orbitrap MS under native conditions using volatile buffers for rapid titre and characterisation

ProA-MS using MAbPac™ Protein A coupled to QE-

Protein A affinity chromatography of bevacizumab using a MAbPac™ Protein A column on a Thermo Scientific™ Vanquish™ Flex UHPLC coupled to a Q Exactive™ UHMR Hybrid Quadrupole-Orbitrap™ Mass Spectrometer




Investigating the pH dependency of the interaction




- Considering that native like MS spectra were observed at low pH, the pH dependence and stoichiometry of the mAb /ProA interaction was investigated using SEC-MS on a Thermo Scientific™ MAbPac™ SEC-1 size exclusion chromatography column
- Stoichiometry appeared consistently at a 1:1 mAb / ProA complex
- Clear pH dependency of the interaction observed until pH lowered to below pH 4.5
- Under classic acidic buffer elution conditions, mAb appears to undergo a reversible confirmational shift

Method performance assessment






Linearity assessment of mAb spiked into cell culture media at levels from 100 µg to 0.5 µg, excellent response and sensitivity and mass accuracy was maintained at < 25 ppm even at the lowest spiking levels evaluated

Application to various mAbs and antibody samples



Application for at-line process monitoring



- ProA-MS applied at-line to samples collected from IgG1 producing bioreactors
- Method provided a rapid insight into glycoform abundances and alterations over various days
- Lowering temperature had the biggest impact on glycosylation, move towards more complete galactosylation

Characterisation Workflows on Vanquish Neo

PQA Analysis of NIST mAb using nano LC-MS/MS


Sample Preparation




NIST mAb

In solution digest:

- Reduction
- Alkylation
- Clean up
- Trypsin 30min @ 37°C



nano LC-MS/MS



Acquisition	DDA Top 20
Column	EasySpray 50cm x 75um
Flow rate	250 nl/min, 45C
Gradient	2-35% ACN in 55 min, 40-45% in 5 min
MS1	60k Res, m/z 200-2000, RF Lens 40%, AGC 100%, max IT 25 ms
MS2	Isolation window 1.2 m/z, NCE 28, 15k Res, AGC 50%, max IT 50 ms
	10s dyn excl, 10ppm tol, charge state 2-7, intensity threshold 5.0e3

Challenge: Detection of low abundant quality attributes!

Adapted from Jakes et al, JASMS, 2021 - <https://pubs.acs.org/doi/pdf/10.1021/jasms.0c00432>


Millán-Martín et al, Anal & Bioanal Chem, 2020 - <https://link.springer.com/article/10.1007/s00216-020-02809-z>

 nibrt
National Institute for
Bioprocessing Research
and Training


Sequence Coverage

NIST mAb injection	Sequence Coverage [%]		Number of MS peaks	
	Light Chain	Heavy Chain	Light Chain	Heavy Chain
1000 ng	96.24	98.44	229	813
750 ng	100.00	98.44	210	805
500 ng	100.00	98.44	200	776
250 ng	100.00	98.00	198	714
100 ng	100.00	97.10	167	584
50 ng	100.00	97.10	132	489
10 ng	98.59	96.21	73	274

NIST mAb Heavy Chain




NIST mAb Light Chain




Sequence coverage map, NIST mAb dilution series: 10 ng injections in triplicate, Easyspray 50 cm column (without trap).

10 peptides selected for evaluation of NIST mAb




Reproducibility



	Peptide Sequence	Peak Area (Avg.)	%CV (Area) (<=10%)	Avg. RT (min)	%CV (RT) (<=2%)	Avg. FWHM (s)	%CV (FWHM) (<=10%)	Min. Mass Error (ppm)	Max. Mass Error (ppm)
1	VEIKR	1.15E+10	0.41%	10.81	0.13%	1.5	2.84%	-1.42	0
2	NQVVLK	2.86E+10	1.55%	16.32	0.12%	4.92	3.27%	-0.57	0.04
3	VDNALQSGNSQESVTEQDSK	3.26E+10	0.63%	22.81	0.11%	5.18	4.72%	-1.14	-0.34
4	DTLMISR	2.88E+10	0.68%	28.21	0.11%	4.95	4.88%	-0.19	0.54
5	SLSLSPG	1.43E+10	0.70%	32.12	0.09%	6.16	3.77%	0	0
6	DIQMTQSPSTLSASVGDR	3.34E+10	0.25%	35.43	0.08%	5.38	5.42%	0.11	1.01
7	FNWYVVGVEVHNAK	6.77E+09	1.30%	34.86	0.12%	5.89	3.34%	0.4	1.13
8	GFYPSDIAVEWESNGQPENNYK	3.14E+10	4.07%	44.93	0.07%	6.94	2.87%	-0.73	0.04
9	VVSVLTVLHQDWLNGK	8.82E+10	6.31%	46.16	0.05%	5.78	2.66%	-0.22	0.59
10	ALEWLADIWWDDKK	5.14E+10	8.08%	51.47	0.08%	5.03	2.22%	-1.36	0.07

* 100 ng injections in triplicate, Easyspray 50 cm column (without trap).

Robustness and Sensitivity




Extracted Ion Chromatogram

The chromatogram displays multiple stacked traces representing different injection amounts of SLSLSPG. The y-axis is labeled 'counts' and ranges from 0.0e0 to 1.6e10. The x-axis is labeled 'min' and ranges from 22 to 34. The peak for SLSLSPG[Lys] is visible around 32 minutes, with intensity increasing as the injection amount increases.

Parameter	Value
σ	3.13E+08
Slope	1.56E+08
R^2	0.9979
LOD	6.63 ng
LOQ	20.10 ng

NIST mAb dilution series: 1000-10 ng injections in triplicate, Easyspray 50 cm column (without trap).
Calibration curve range 250 – 10 ng (due to poor peak shape at high injection amounts).




PQA Analysis



Peptide	Description	%Mod. (Avg.)	%CV (Mod.) (<=15%)	Pass or Fail
GFYPSDIAVEWESNGQPENNYK	Deamidation	1.88	12.39%	Pass
DTLMISR	Oxidation	1.89	1.61%	Pass
WQQGNVFSCSVMHEALHNHYTQK	Oxidation	1.36	0.92%	Pass
SLSLSPG	C-term Lys	16.15	0.65%	Pass
EEQYN[A2G1F]STYR	N-Glycan	40.56	0.50%	Pass
EEQYN[A2G0F]STYR	N-Glycan	38.75	0.86%	Pass
EEQYN[A2G2F]STYR	N-Glycan	9.56	1.89%	Pass
EEQYN[A1G0F]STYR	N-Glycan	5.23	2.41%	Pass

NIST mAb 100ng replicates, n=6


Nano-LC based MAM workflow for cell culture screening



Challenge: Limited sample amount!

* Proof of concept experiment – IgG1 was spiked in at concentrations based on previously published cellular productivity. SP3 digestion was performed in triplicate.

RT precision across 12 injections




Day	Cells/mL	qP low (10pg)	qP high (50pg)
3	1.02e06	6.13	30.65
5	1.85e06	18.58	92.91

Peptide	ADYEK	VQWK	SLSLSPG[Lys]	ALPAPIEK	DTLMISR	FNWYVDGVE VHNAK	VDNALQSGNSQESVTEQ DSKDSTYSLSSLTLSK	VVSVLTVLHQD WLNGKEYK	GLEWIGAIYPGN GDTSYNQK	Q[NH3 loss]IVLSQ SPAILSASPGEK	STYYGGDWYFNWV GAGTTVTVAASKT
Average RT	10.78	15.9	22.66	24.58	27.99	34.51	36.69	41.75	46.32	49.38	65.27
%CV (RT)	0.25%	0.33%	0.13%	0.13%	0.13%	0.12%	0.11%	0.08%	0.08%	0.04%	0.05%
Pass or Fail	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass


PQA Analysis

138 total components (considering all charge states), 29 attributes monitored




PQA Analysis

IgG1 Quality Attributes (n=12)




PQA Analysis

N-Glycosylation (n=12)




Nano-LC workflow for HCP detection



Challenge: Dynamic range!
Low concentration of HCPs vs. high abundant mAb derived peptides.

Host Cell Protein (HCP) detection in IgG1 samples






- ✓ 141 detected HCPs (min. of 2 unique peptides)
- ✓ 65 HCPs quantified (LFQ, no missing values)


Accession	Description	# Unique Peptides
G3H0L9	Cathepsin B	12
G3HNJ3	Clusterin	22
G3HMD1	Glyceraldehyde-3-phosphate dehydrogenase	6
G3IDL7	Heat shock cognate 71 kDa protein	4
G3H354	Heat shock protein HSP 90-alpha	10
G3HC84	Heat shock protein HSP 90-beta	9
G3H2T4	Histone H2B	4
G3GYP9	Peroxiredoxin-1	7
G3HC31	Protein S100	2

Host Cell Protein (HCP) detection in IgG1 samples

Pearson correlation = 0.973










AAV Peptide Mapping Workflow



Challenge: low concentration and price of AAV samples!

AAV Peptide Mapping Workflow



200ng injections, 3 technical replicates – 50 cm vs. 15 cm EasySpray Neo Column


Sequence Coverage of VPs

Method	VP1	VP2	VP3
50cm 20min	100	100	100
50cm 60min	99.4	100	100
15cm 20min	100	100	100
15cm 60min	98.3	98	100



Monitoring potential quality attributes

Method	PTMs
15cm 20min	57
15cm 60min	55
50cm 20min	57
50cm 60min	55



Summary / Take home messages

System preparation:

Vanquish Neo significantly **reduces required hands-on time**
User friendly interface and built in leak tests facilitate **easy change
of trap-elute/direct injection workflows**

Performance:

Vanquish Neo hyphenated to Exploris 480 enables **highest
reproducibility and robust performance**

High sensitivity at low flow rates facilitates of various
biotherapeutics even at low sample concentrations in-depth
analysis

Ease of obtaining information rich, **high-confidence** results

